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ABSTRACT
In breast cancer, constitutive activation of NF-κB has been reported, however, the 
impact of genetic variation of the pathway on patient prognosis has been little studied.  
Furthermore, a combination of genetic variants, rather than single polymorphisms, 
may affect disease prognosis. Here, in an extensive dataset (n = 30,431) from the 
Breast Cancer Association Consortium, we investigated the association of 917 SNPs in 
75 genes in the NF-κB pathway with breast cancer prognosis. We explored SNP-SNP 
interactions on survival using the likelihood-ratio test comparing multivariate Cox’ 
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INTRODUCTION
Aberrant regulation of the NF-κB is common in 
human breast cancer cell lines and in primary tumor cells 
from patients with breast cancer [1, 2]. Dysregulation 
of the NF-κB signaling pathway has been shown to 
contribute to cancer development and progression as 
well as to chemo-and radiotherapy-resistance [3], and 
selective inhibition of the NF-κB-activating pathway 
genes has been reported to sensitize breast cancer cell 
lines to doxorubicin [2, 4-6]. To date, few studies have 
investigated whether inherited genetic variation in the NF-
κB pathway is associated with breast cancer prognosis [7, 
8]. Our previous research indicates a link between breast 
cancer outcome and the NQO1 gene, the expression and 
function of which is closely connected to the NF-κB 
network [9-12]. Recently, a breast cancer survival study 
on SNPs within or in the 100kb flanking region of genes 
implicated in human immunology and inflammation 
suggested that rs4458204 affects breast cancer survival 
in patients with ER-negative tumors who have been 
treated with chemotherapy. Rs4458204 is located 41.5 kb 
upstream of the chemokine ligand 20 (CCL20) which is a 
downstream target of NF-κB [13].
Two sub-pathways are proposed to account for the 
NF-κB activation: the canonical, and the non-canonical 
NF-κB pathway. The canonical pathway, also referred to as 
the classic pathway, mainly activates the NF-κB1 dimers 
(RelA:p50). Under resting conditions, the NF-κB1 dimers 
are bound to IκB-α and retained in an inactive form in 
the cytoplasm. When the canonical pathway is stimulated 
by pro-inflammatory signals (e.g. TNFα) through their 
receptors (e.g.TNFR1) the signal is transduced through 
a FADD and TRAF2 assembly to the IKKβ-NEMO 
complex which phosphorylates the IκB molecules, and 
this in turn leads to degradation of IκB-α. Upon IκB-α 
degradation, the NF-κB1 dimers are free to translocate to 
the nucleus where they activate target gene transcription. 
The canonical pathway therefore consists of the ligands, 
the receptors, the IKK complex, IκB proteins and NF-κB 
dimers which together can lead to either cell survival or 
cell death [14-17].
The non-canonical pathway involves the activation 
of IKKα by the TNF cytokines (e.g. BAFF and LT-β 
through their receptors (e.g. BAFFR and TNFR3, also 
known as LT-βR). This results in the phosphorylation and 
degradation of p100, and the subsequent formation of the 
p52 (processed NF-κB2) and RelB complex. The p52-
RelB complex then translocates to the nucleus and induces 
the expression of a different set of target genes than those 
induced by the canonical pathway [18, 19]. Some overlap 
exists between the canonical and non-canonical pathways: 
signals associated with cell survival or apoptosis can be 
transmitted via the same ligand and/or receptor in both 
pathways [20].
Here, we investigated the association between 
breast cancer patient survival and SNPs residing within 
or in the 50-kb flanking region of 75 genes in the NF-
κB activating pathway using an extensive data set of the 
Breast Cancer Association Consortium (BCAC). It is 
plausible that a combination of genetic variants, rather 
than a single polymorphism, may affect the prognosis for 
a complex disease such as breast cancer. For instance, a 
recent combinatorial RNAi screening of cancer genes, 
which are frequently co-altered in primary breast cancer, 
identified interacting gene pairs that associate with patient 
survival [21]. Here, in addition to a single SNP association 
study, we present two-SNP interaction analysis, which 
is more feasible to conduct and interpret than multiple-
SNP interactions [22]. The panel of markers included 917 
SNPs for 75 candidate genes involved in the activation 
of the NF-κB pathway available in a custom Illumina 
iSelect genotyping array designed for the Collaborative 
Oncological Gene-Environment Study (iCOGS) [23].
RESULTS
SNP association with prognosis
Altogether 30,431 invasive breast cancer cases of 
European ancestry from 24 BCAC studies participated 
in this study (Supplementary Table 1) [23]. A total of 
917 SNPs available in the BCAC iCOGS data set (See 
material and methods) were included in the analyses to 
regression models of SNP pairs without and with an interaction term. We found two 
interacting pairs associating with prognosis: patients simultaneously homozygous 
for the rare alleles of rs5996080 and rs7973914 had worse survival (HRinteraction 6.98, 
95% CI=3.3-14.4, P=1.42E-07), and patients carrying at least one rare allele for 
rs17243893 and rs57890595 had better survival (HRinteraction 0.51, 95% CI=0.3-0.6, P = 
2.19E-05).  Based on in silico functional analyses and literature, we speculate that the 
rs5996080 and rs7973914 loci may affect the BAFFR and TNFR1/TNFR3 receptors and 
breast cancer survival, possibly by disturbing both the canonical and non-canonical 
NF-κB pathways or their dynamics, whereas, rs17243893-rs57890595 interaction on 
survival may be mediated through TRAF2-TRAIL-R4 interplay. These results warrant 
further validation and functional analyses.
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investigate the association of the SNPs and breast cancer 
patient survival. All SNPs were located within, or in a 
50kb flanking region of 75 candidate genes involved in 
the activation of the NF-κB pathway. All survival analyses 
were adjusted for study. Ten-year overall survival (death 
due to breast cancer or other reasons) was used as the 
end-point in these analyses for reasons of data availability 
and consistency. The survival analyses of the 917 single 
SNPs studied here revealed no significant (PCorrected > 0.01) 
association with patient survival (Supplementary Table 2). 
To discover plausible epistatic/non-additive interacting 
SNPs associating with prognosis, we conducted a two-SNP 
interaction survival analysis using the likelihood ratio test 
comparing multivariate Cox’ regression models of pairs of 
SNPs without and with an interaction term (SNP1+SNP2 
vs. SNP1+SNP2+(SNP1*SNP2), respectively) (see 
methods/statistical analyses). Using Cox proportional 
hazard models, the recessive (AA = 0, Aa = 0, aa = 1) and 
dominant (AA = 0, Aa = 1, aa = 1) models were assessed 
for all the SNPs. With a sample size of 30,431 with 3375 
Table 1: Multivariate Cox’ regression models to assess the interaction between rs5996080 and rs7973914 by recessive 
model of inheritance.
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events and the average MAF of 23.4%, we had 80% power 
to detect interaction terms with HR above 1.4 (or 1/1.4 = 
0.6) and HR of 6.2 (or 1/6.2 = 0.16) in the dominant and 
recessive models respectively. We found one interacting 
SNP pair, rs5996080 and rs7973914, in the recessive 
model and another one, rs17243893 and rs57890595, in 
the dominant model which passed these HR thresholds 
with a corrected p-value threshold <0.05.
Under the recessive model, a pair-wise interaction 
between rs5996080 (A/G, MAF = 8%) and rs7973914 
(G/A, MAF = 40%) was found to be associated with 
patient survival: patients carrying the homozygous rare 
allele for both SNPs (rs5996080-GG, rs7973914-AA) 
had worse overall survival compared to carriers of at least 
one common allele (HRinteraction 6.98, 95% CI = 3.3-14.4, 
P = 1.42E-07, Table 1). The interaction was statistically 
significant in a likelihood-ratio test, compared to a Cox 
model without an interaction term (Plikelihood-ratio-corrected = 
0.003) (Table 1). Absolute uncorrected survival rates of 
genotype combination categories were compared using 
Kaplan-Meier curves (Figure 1). Supplementary table 3 
lists the likelihood-ratio test p values obtained also for 
the SNPs nearby or in LD with the rs5996080-rs7973914 
interacting pair. Due to the limited power (small number 
of patients and less than 5 events per subgroup), no 
subgroup analyses by ER status, lymph node status, and 
chemotherapy treatment (see methods) were conducted for 
this interacting pair.
Using the dominant model, we found a pair-wise 
interaction between rs17243893 (A/G, MAF = 5%) and 
rs57890595 (A/C, MAF = 11%) to be associated with 
patient survival: Patients simultaneously carrying at least 
one rare allele for both variants (rs17243893-AG+GG, 
rs57890595-AC+CC) had better overall survival compared 
to the patients with common homozygous genotypes 
(HRinteraction 0.51, 95% CI = 0.3-0.6, P = 2.19E-05)(Table 
2). The interaction was statistically significant (Plikelihood-ratio-
corrected = 0.005) (Table 2). Absolute uncorrected survival 
rates of genotype combination categories were compared 
using Kaplan-Meier curves (Figure 2). Supplementary 
table 4 lists the likelihood-ratio test p values obtained 
also for the SNPs nearby or in LD with the rs17243893-
rs57890595 interacting pair. The effect of the SNP-SNP 
interaction on patient survival was consistent between the 
subgroups studied (ER positive vs. negative, lymph node 
positive vs. negative, chemotherapy-treated vs. non-treated 
patients) and was not confined to any specific subset of 
patients (Supplementary Table 5, Supplementary Figure 
1 ).
Association of the interacting pairs with tumor 
characteristics
The association between clinical and 
histopathological features of tumors and genotype 
combinations of the interacting SNP pairs is summarized 
in Supplementary Table 6a and b. No significant 
association was found for the SNP pair from the recessive 
model. The interacting SNP pair found with the dominant 
model associated with nodal status (N), with a borderline 
significant p value of 0.010, and may also associate with 
Figure 1: Kaplan-Meier survival curves of the combination genotypes of rs5996080 and rs7973914 (recessive model)
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metastasis at diagnosis (M), but the difference was not 
statistically significant. Carriers of the protective genotype 
combinations (rs17243893-AG+GG and rs57890595-
AC+CC) had also a lower frequency of nodal or distant 
metastasis. 
Corresponding genes in the NF-κB activating 
pathway
Of the recessive SNP pair, rs5996080 resides 
in chromosome 22, in the flanking region (31.5 kb 
Table 2: Multivariate Cox’ regression models to assess the interaction between rs17243893 and rs57890595 by 
dominant model of inheritance.
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downstream) of the NF-κB pathway gene BAFFR (B-cell 
activating factor receptor, also known as TNFRSF13C). 
rs5996080 is in strong linkage disequilibrium (r2 = 1) with 
15 SNPs located in BAFFR. The other SNP in the pair, 
rs7973914, is located on chromosome 12, 8kb upstream 
of the NF-κB pathway gene TNFR3 (TNFR superfamily 
member 3, also known as LTBR)) and 27kb upstream 
of TNFR1 (tumor necrosis factor receptor superfamily, 
member 1a, also known as TNFRSF1A). rs7973914 resides 
in a short haplotype block with very few SNPs. 
Of the dominant model SNP pair, rs17243893 is 
located in chromosome 9, within the intron of NF-κB 
pathway gene TRAF2 (TNF receptor associated factor 2). 
The other SNP in the pair, rs57890595, is located in the 
chromosome 8, and lies in the intronic region of NF-κB 
pathway gene TRAIL-R4 (TNF-related apoptosis ligand 
receptor 4, also known as TNFRSF10D). Other nearby 
genes include TNFRSF10A and TNFRSF10C.
Annotation of established functional elements in 
the site of interacting pairs based on ENCODE 
data
To investigate the possible functional role of 
the interacting SNPs or other SNPs in the surrounding 
LD regions (r2 > 0.2), we utilized the ENCODE-based 
functional annotations at the Haploreg and RegulomeDB 
databases in order to determine whether they are located 
within genomic regulatory elements in human mammary 
epithelial cells (HMEC).
For the recessive SNP pairs, rs5996080 and 
rs7973914, 35 of the SNPs in the rs5996080 locus may 
potentially lead to alteration of regulatory elements as 
defined by transcription factor binding motifs, histone 
modifications, DNase sites and protein binding regions 
in HMEC. Of these SNPs, 26 are in strong LD with 
rs5996080 (r2 and/or D’ >0.8). The Haploreg annotation 
indicated that in HMECs, the majority of rs5996080 
proxies are located in regions with enhancer histone marks. 
We identified 10, 22, and 6 SNPs mapping to regions 
with promoter histone marks, enhancer histone marks, 
and DNase hypersensitivity sites, respectively. Of the 
SNPs mapping to DNase hypersensitivity sites, four were 
overlapping with regions with promoter histone marks, 
and three were overlapping with regions with enhancer 
histone marks (Supplementary Table 7a). According to 
ENCODE data, rs117492772 (r2 = 0.86 with rs5996080) 
alters a putative transcription factor binding motif of NF-
κB. The rs5996080 SNP itself changes the putative motif 
binding of ERα-a. As for rs7973914, four SNPs in the LD 
region map to regulatory regions with enhancer histone 
marks in HMEC. Of these, three SNPs are in strong LD 
with rs7973914 (r2 and/or D’ >0.8) (Supplementary Table 
7b).
For the dominant model SNPs, rs17243893 and 
Figure 2: Kaplan-Meier survival curves of the combination genotypes of rs17243893 and rs57890595 (dominant model)
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rs57890595, in silico analysis was limited by the short/
undefined haplotypes, as indicated above. Haploreg 
and RegulomeDB annotation maps two SNPs in the 
rs17243893 locus (rs17243893 and rs35253986, r2 = 
1 and 0.27, respectively) in HMEC to regions with 
enhancer histone mark and DNase hypersensitivity sites. 
(Supplementary Table 7c). No SNPs mapped to HMEC 
regulatory elements at the rs57890595 locus.
Association of the interacting SNPs and the 
expression levels of nearby NF-κB activating 
pathway genes
To further evaluate whether the interacting pair 
SNPs might have a functional effect or be related to other 
functional SNPs that affect the expression level of their 
corresponding genes in NF-κB activating pathway, we 
performed eQTL analysis using two publicly available 
data sets consisting of genotype and gene expression data: 
TCGA and METABRIC. To this end, we analyzed all 
available SNPs in the LD region (r2 >0.1). The interacting 
SNPs themselves were not genotyped in either of the data 
sets, but are represented through LD.
For the recessive model SNP pair, an rs5996080 
proxy (rs9620000, r2 = 1) consistently associated with 
higher expression of BAFFR in both the TCGA tumor 
(P = 0.049) and METABRIC data sets (P = 0.003). We 
also detected one rs5996080 proxy (rs17002737, r2 = 
0.79) which associated with the expression of TNFR1 (P 
= 0.049), and several SNPs in the locus that correlated 
positively with the expression of TNFR3 (rs2269658: 
r2 = 0.5, D’ = 0.8, p = 0.00006; rs9620000: r2 = 1, p = 
0.003; rs5996088: r2 = 1, p = 0.002; rs1023497: r2 = 0.4, 
D’ = 1, p = 0.01; and rs133367 r2 = 0.2, D’ = 1, p = 0.04). 
There were only four proxies of rs7973914 available in 
the TCGA/METABRIC data, and none of them associated 
significantly with the expression level of either TNFR1/3 
or BAFFR.
For the dominant model SNP pair, rs17243893 and 
rs57890595, we did not find any significant correlation 
between the expression of the few rs17243893 proxies 
and TRAF2, nor with TRAIL-R4. We identified one SNP 
rs57890595 in the TCGA tumor data (rs12546238, r2 = 
0.2), and one (rs4278155, r2 = 0.2) in the normal tissue data 
(n = 85), that correlated with the expression of TRAIL-R4 
(P = 0.004). Another SNP in the region rs57890595 
Figure 3: Genes annotated to the SNP pair significant in the recessive model. BAFFR activates the NF-κB, mainly through the 
non-canonical pathway whereas TNFR1 activates the canonical NF-κB pathway and TNFR3 activates both pathways. The survival effect 
observed in the SNP interaction analyses might be due to simultaneous perturbation of BAFFR and TNFR1/TNFR3 which might affect 
both the canonical and the non-canonical NF-κB pathways or their dynamics. Genes annotated to the SNP pair significant in the dominant 
model: TRAF2 functions as a molecular bridge linking the receptors to downstream kinases. TRAIL-R4 has been suggested to activate the 
non-canonical pathway through TRAF2-NIK-IKK cascade. The observed survival effect by SNP interaction might be mediated through 
TRAF2 and TRAIL-R4 interplay.
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(rs4871880, r2 = 0.1) associated with the expression level 
of TRAF2 (P = 0.0006) in the METABRIC data.
DISCUSSION
The postulated association of the NF-κB pathway 
with tumor progression and patient survival could be 
affected by interactions of multiple loci, in addition to 
single locus effects. Here, we aimed to highlight plausible 
epistatic/non-additive interactive effects of SNPs near 
relevant genes for further validation and functional 
analyses. We explored the NF-κB pathway by assessing 
two-way interactions of 917 SNPs in 75 genes within 
the NF-κB activating pathway and found evidence of 
interaction between two pairs of SNPs corresponding to 
five genes: rs5996080 and rs7973914 by the recessive 
model, and rs17243893 and rs57890595 by the dominant 
model. We discovered these associations through a semi-
parametric approach, with large sample size, and stringent 
p value and Hazard ratio criteria determined by power 
analysis for each model of inheritance. None of the SNPs 
identified here exerted statistically significant survival 
effects individually.
Using the recessive model, we identified an 
interaction between rs5996080, near the gene BAFFR, 
and rs7973914, located in the proximity of TNFR1 and 
TNFR3. While the SNPs in either of the two loci did 
not individually associate with survival, they appear 
to have an interactive prognostic effect: compared to 
carriers of at least one common allele, the patients 
carrying the homozygous rare allele of both SNPs had 
worse 10-year overall survival. We did not observe any 
statistically significant association between the interacting 
genotype combination and the clinical and pathological 
characteristics of the tumors, although it must be noted 
that we had low power to detect such an association in 
the first place due to the limited number of cases in the 
interacting genotype category.
The candidate NF-κB genes (BAFFR, TNFR1 
and TNFR3) in these loci are in general TNF receptors 
(Figure 3). Physically, rs5996080 resides in the intron of 
another gene, SREBF2 (sterol regulatory element-binding 
transcription factor-2), and rs7973914 is in the intron 
of SCNN1A (sodium channel non-voltage-gated 1 alpha 
subunit). SREBF2 gene is a lipogenesis transcription 
factor which has been shown to be up-regulated in a breast 
cancer cell line (HCC1143) compared to normal mammary 
epithelial cells (MCF10A) [24]. SREBF2 negatively 
regulates SMAD3 [25] which is demonstrated to physically 
interact with IKKα (the NF-κB activator). Through this 
interaction, IKKα is suggested to control the binding of 
the SMAD complex to DNA and therefore, contribute to 
the tumor-promoting function of the TGF-beta/SMAD 
signaling pathway in human MDA-MB-231 breast cancer 
cell line. However, this process appears to be NF-κB-
independent [26, 27]. For SCNN1A, a read-through fusion 
transcript of SCNN1A-TNFR1 has been recently identified 
in breast cancer cell lines as well as in primary breast 
cancer tumors, and was not detected in normal tissues 
[28]. Interestingly, an rs5996080 proxy (rs5996088: r2 = 
1) associates with decreased expression of SREBF2 and 
SCNN1A (p = 0.014 and p = 0.0007 respectively; TCGA 
dataset only) which might also contribute to the observed 
interactive survival effect. BAFFR, the candidate NF-κB 
gene in the locus with significant eQTL association with 
rs5996080, is one of the best known receptors involved 
in the non-canonical NF-κB pathway and is known to 
be the physiological signal that promotes the processing 
of RelB/P100 to ReLB/P52 resulting in the activation of 
NF-κB2 [29]. Although BAFFR preferentially induces the 
non-canonical pathway, it has been suggested to activate 
the canonical pathway as well. However, contrary to its 
activating role in the non-canonical pathway, the BAFFR 
impact on the canonical pathway appears minor, and 
remains ambiguous [30]. TNFR1 signaling, on the other 
hand, activates the canonical RelA/ NF-κB1 pathway 
through the induction of the IKK complex, while 
TNFR3 signaling can activate both the canonical and 
the non-canonical ReLB/NF-κB2 pathways through the 
processing of P100 to P52. Perturbations in the function 
of these genes could therefore be hypothesized to alter the 
dynamics between pro-apoptotic and anti-apoptotic NF-κB 
signaling pathways, which in turn may influence cancer 
progression and outcome, possibly in an epistatic manner. 
While the biological mechanism behind the SNP-SNP 
interaction between these loci can only be speculated on at 
this point, our ENCODE and eQTL analyses indicated that 
SNPs at both of these loci may influence gene expression, 
particularly rs5996080, which associates with the higher 
expression of both BAFFR and TNFR1/TNFR3. This 
is in line with the poor breast cancer survival observed 
in this study, due to the BAFFR-mediated activation of 
the non-canonical pathway contributing to cell survival 
[31, 32] and the suggested involvement of the TNFR3 
signaling in inflammation-induced carcinogenesis [33]. 
Indeed, the blockade of the TNFR3 signaling has been 
used as anti-inflammatory, anti-cancer therapy in some 
experimental models [34, 35]. Additionally, the ENCODE 
data indicated that an rs5996080 proxy (rs117492772, r2 
= 0.86) alters a binding site for the NF-κB transcription 
factor itself, as well as a putative ERα binding site. In light 
of this, it would have been interesting to investigate the 
interaction in subgroups defined by ER status, but such an 
analysis was unfortunately not feasible due to the limited 
number of cases in the interacting genotype category. 
Taken together, we speculate that the combination of the 
rare homozygous alleles for rs5996080 and rs7973914, 
or the causative variants in LD with them, might 
simultaneously compromise the BAFFR and TNFR1/
TNFR3 receptors’ function (Figure 3) and breast cancer 
survival by perturbing both the canonical and the non-
canonical NF-κB pathways or their dynamics. However, 
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it is possible that the observed SNP interaction may be due 
to more complex survival effects by multiple genes in the 
rs5996080 and rs7973914 loci. This speculation requires 
further validation, and functional analyses.
Under the dominant model, we identified an 
interaction between rs17243893 and rs57890595: 
compared to the patients with wild type homozygous 
genotypes, patients carrying at least one rare allele for 
both variants have a better 10-year breast cancer survival. 
Interestingly, the genotype combination associating 
with improved survival also tended to associate with 
negative axillary lymph node status and, although not 
to a statistically significant degree, less frequent distant 
metastasis at diagnosis.
rs17243893 is an intronic SNP located in TRAF2, 
an oncogene which activates NF-κB in epithelial cancers 
including breast cancer, by activating the NIK-IKK 
complex (Figure 3). TRAF2 function is best characterized 
in the TNFR1 signaling pathway [36] . TNFRSF signaling 
is primarily regulated via TRAFs, and by the activation of 
NF-κB [37]. The other SNP in this pair, rs57890595, lies 
in the intronic region of the TRAIL receptor TRAIL-R4. 
Evidence suggests that NF-κB activation by TRAIL-R4 
takes place through a TRAF2-NIK-IKK cascade. This 
implicates an interplay between TRAF2 and TRAIL-R4 
that ultimately promotes cell survival [38]. In the site of 
rs17243893, our Haploreg analyses show regulatory motif 
alteration for AP-1: a-c-Fos and c-Jun family member 
which has been suggested to be reciprocally activated by 
NF-κB. It has been shown that the inhibition of NF-κB 
results in the inhibition of fos expression and consequently 
the AP-1 activity in pancreatic adenocarcinoma cell lines 
(MDApanc-28) [39]. Unfortunately, since neither of 
the two SNPs in this pair was represented in the TCGA 
or METABRIC gene expression dataset, we have no 
compelling evidence that links this pair with the expression 
of TRAIL-R4 and TRAF2. Nevertheless, these two genes 
remain plausible candidates for the prognostic interactive 
effect: TRAF2 /TRAIL-R4-mediated NF-κB activation 
results in cell survival which would be consistent with the 
poor prognosis observed in this study under the hypothesis 
that the rs17243893-rs57890595 (or the causative variants 
in LD with them) interaction potentiates or otherwise 
dysregulates this signaling cascade.
In summary, in analyses of 917 SNPs in 75 genes 
of the NF-κB activating pathway, we identified two SNP-
SNP interactions to be associated with survival of the 
breast cancer patients. We have searched for regulatory 
elements in these loci and examined their influence on 
gene expression, and we propose a biological rationale 
for the observed effects. Yet, one must remain aware 
of potential data interpretation biases introduced by 
pathway-based SNP selection. For example, long-
distance regulatory effects may extend well beyond the 
local LD block, and the observed prognostic interactions 
may therefore be caused by genes other than the primary 
candidate genes or their neighbors. However, we did not 
observe significant association between the SNPs in LD 
with the interacting SNP pairs and the expression level of 
genes elsewhere in the genome in TCGA and METABRIC 
dataset consistently. A weakness of our study is that 
large-scale analyses are potentially at the risk of inflated 
type I error. As even seemingly significant results can 
easily be false positives in an underpowered analysis, to 
address this, we chose to use power calculations to define 
robust HR thresholds for this study [40]. Nevertheless, 
in addition to the multiple testing correction methods 
applied here, further validation of the interaction SNP 
pairs is required. Moreover, with this approach we were 
only able to discover interactions with fairly large effect 
sizes, while any true interactive effects with low hazard 
ratios would remain undetected. Furthermore, even though 
the SNPs were selected for their proximity with the NF-κB 
activating pathway genes and the observed survival effects 
are consistent with a plausible biological rationale, it is 
also possible that the observed effect is partially or wholly 
caused by other nearby genes, especially as the rs5996080 
and rs7973914 loci are physically located in introns of 
other, non-NF-κB, genes. Further functional studies are 
required to identify the causal elements of the detected 
effects on patient survival.
The prognosis of complex diseases such as breast 
cancer is a dynamic process which is influenced by a large 
number of clinicopathological factors, and is likely also 
affected by a combination of genetic variants. Compared 
to an agnostic genome wide analysis, the pathway-oriented 
approach tested here may increase the chance of obtaining 
biologically meaningful results with statistical significance 
regarding SNP-SNP and gene-gene interactions in a 
prognostic and/or predictive context, although it also 
necessarily introduces a degree of bias based on the 
initial hypothesis. These findings can then contribute to 
functional analyses elucidating the underlying mechanisms 
of the interplay between genes involved in the NF-κB 
pathway, and their influence on breast cancer progression 
and survival.
MATERIAL AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international guide. 
All participants in these studies had provided written 
consent for the research. All participating studies were 
approved by the respective ethical review boards and ethics 
committees: ABCFS (The University of Melbourne Health 
Sciences Human Ethics Sub-Committee (HESC)), ABCS 
(Leiden University Medical Center (LUMC) Commissie 
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Medische Ethiek and Protocol Toetsingscommissie 
van het Nederlands Kanker Instituut/Antoni van 
Leeuwenhoek Ziekenhuis), BBCC (Friedrich-Alexander-
Universitat Erlangen-Nurnberg Medizinische Fakultat 
Ethik-Commission), BSUCH (Medizinische Fakultat 
Heidelberg Ethikkommission), CGPS (Kobenhavns Amt 
den Videnskabsetiske Komite), ESTHER(Ruprecht-
Karls-Universitat Medizinische Fakultat Heidelberg 
Ethikkommission), HEBCS (Helsingin ja uudenmaan 
sairaanhoitopiiri (Helsinki University Central 
Hospital Ethics Committee)), KARBAC (Lokala 
Forskningsetikkommitten Nord), KBCP (Pohjois-Savon 
Sairraanhoitopiirin Kuntayhtyma Tutkimuseettinen 
Toimikunta), kConFab/AOCS (kConFab: The Queenland 
Institute of Medical Research Human Research Ethics 
Committee (QIMR-HREC)), LMBC (Commissie 
Medische Ethiek van de Universitaire Ziekenhuizen 
Kuleuven), MARIE (Ruprecht-Karls-Universitat 
Medizinische Fakultat Heidelberg Ethikkommission), 
MCBCS (Mayo Clinic IRB), MCCS( The Cancer Council 
Victoria Human Research Ethics Committee), MEC 
(University of Southern California Health Sciences 
Campus IRB), OBCS (Ethical Committee of the Medical 
Faculty of University of Oulu and Northern Ostrobothnia 
Hospital District Ethical Committee), OFBCR (Mount 
Sinai Hospital Research Ethics Board), ORIGO (Medical 
Ethical Committee and Board of Directors of the Leiden 
University Medical Center (LUMC)), PBCS (National 
Institute of Health (NIH) IRB), pKARMA (Regionala 
Etikprovningsnamnden i Stockholm (Regional Ethical 
Review Board in Stockholm)), RBCS (Medische Ethische 
Toetsings Commissie Erasmus Medisch Centrum), 
SASBAC (Regionala Etikprovningsnamnden i Stockholm 
(Regional Ethical Review Board in Stockholm)), SBCS 
(South Sheffield Research Ethics Committee), SEARCH 
(Multi Centre Research Ethics Committee (MREC)).
Study subjects
We used primary data from the studies participating 
in BCAC [23]. All studies had received approval of 
relevant local human ethical or institutional boards (see 
Ethics statement). For each study, the minimum number 
of events (death) required to enter the analyses was 10. A 
total of 24 studies contributed here, with data on altogether 
30,431 invasive breast cancer cases of European ancestry 
(Supplementary Table 1). The contributing groups 
provided data on conventional prognostic and predictive 
markers: age of diagnosis, tumor grade, size, nodal 
status, metastases at diagnosis, histological type, estrogen 
receptor, progesterone receptor, HER2 status, and follow-
up and vital status [41].
SNP selection and genotyping
We included 917 SNPs available in the BCAC 
iCOGS data set [23], residing within or in a 50kb flanking 
region of 75 candidate genes involved in the activation 
of the NF-κB pathway identified from KEGG hsa04064 
(www.genome.jp/kegg/) (Supplementary Table 8). These 
75 candidate genes included ligands and receptors (e.g. 
TNF, TLR1-4, and TNFRSF10A and B), membrane 
molecules (e.g. IRAK2), Kinases (e.g. IKBKB), I-kappa-B 
cascade (e.g. IKBKG, IRAK1 and TLR8), cytoplasmic 
sequestering/releasing of NF-κB (e.g. NF-κBIs and 
TNFSFs), transcription factors (e.g. NF-κB1 and RELs); 
but not the T-cell specific elements nor the downstream 
targets of NF-κB [24]. All cases were genotyped as 
previously described using a custom-built Illumina iSelect 
array [23]. The genotypes were called using Illumina’s 
proprietary GenCall algorithm. Details of the quality 
control of the genotype data were described previously 
[23].
Statistical analysis
We performed the statistical analyses using R 
environment for statistical computing version 2.15.2 
(http://www.r-project.org/). P-values for association of 
the SNPs with tumor characteristics were calculated 
using Pearson’s chi-squared tests. Power analyses for the 
survival study were performed using the powerSurvEpi 
package in R. We excluded SNPs with a minor allele 
frequency (MAF) <1%. The 10-year overall survival was 
calculated from the time of diagnosis to the date of death 
due to breast cancer or other reasons (median follow up 
time 5.6 years), or to the date of the last follow up. To 
allow for the inclusion of prevalent cases, time at risk was 
left censored using date of study entry. Survival analyses 
included Log-rank tests for assessing the statistical 
significance of differences between Kaplan-Meier curves 
for survival, and Cox’ regression models for estimating 
the hazard ratios (HR)s. All Cox’ models were adjusted 
for study. All p values reported are from two-sided tests. 
We performed two-way SNP interaction analysis on a 
total number of 917 SNPs for recessive (AA = 0, Aa = 
0, aa = 1) and dominant (AA = 0, Aa = 1, aa = 1) models 
of inheritance. To determine the association of SNP-SNP 
interaction with patients’ survival we used the likelihood 
ratio test to compare multivariate Cox’ regression models 
of pairs of SNPs without and with an interaction term 
(SNP1+SNP2 vs. SNP1+SNP2+(SNP1*SNP2). For 
each pair of SNPs the best model was selected based on 
the likelihood ratio test p value. To adjust for multiple 
testing error we applied the Benjamini-Hochberg post 
hoc method, which is also known to be robust against 
moderate dependency between SNPs, for example linkage 
disequilibrium [42, 43]. For the interaction pairs to be 
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considered significant, we set two stepwise thresholds. 
Firstly, the interactive pairs with p value< 0.01 after 
correction were selected. Secondly, for the selected set of 
interaction pairs to be considered significant, we applied a 
threshold for the HR based on the power analysis for each 
model. With a sample size of 30,431 with 3375 events 
and the average MAF of 23.4%, in the dominant and 
recessive models we had 80% power to detect interaction 
terms with HR > = 1.4 (or 1/1.4 = 0.6) and HR of > = 
6.2 (or 1/6.2 = 0.16), respectively. In addition, for the 
SNP pairs with significant interaction survival effects, 
subgroup analyses were performed to investigate whether 
the survival effect was differentially affected by tumor/
patients characteristics and/or treatment. However, the 
analyses were limited to the subgroups with 5 or more 
death events (i.e. by ER status, lymph node status, and 
chemotherapy treatment).
Expression quantitative trait loci (eQTL)
In order to analyze the correlation between the loci 
of interest and the gene expression we utilized the data 
from The Cancer Genome Atlas (TCGA) and METABRIC 
project [44, 45]. From TCGA data set, we retrieved both 
peripheral blood DNA SNP genotype data, and expression 
data for 913 primary breast tumors. Additionally, of 913 
TCGA cases, we also retrieved expression data from 
85 healthy breast tissues. The TCGA expression data is 
from level 4 RNA-Seq (upper quartile normalized RSEM 
expression estimates). The TCGA matched peripheral 
blood DNA SNP genotype data is from level 2 Birdseed 
files (genotyped on Affymetrix Genome-Wide Human 
SNP Array 6.0 array and processed using Birdseed). 
The METABRIC raw genotype data (Affymetrix SNP 
6.0 platform) was downloaded from European Genome-
phenome Archive (cancergenome.nih.gov). The raw 
genotype data was processed with Affymetrix Genotyping 
Console Software following the best practices of 
Affymetrix SNP 6.0 analysis workflow provided by 
the program provider. The workflow included a quality 
control step with Contrast QC, a metric that captures the 
ability of an experiment to resolve SNP signals into three 
genotype clusters, applying the sample quality threshold 
of < 0.4 (the Contrast QC is typically greater than 0.4) 
and genotype calling using Birdseed v2 including the 
genotypes with call rate of ≥95%. After the QC process 
1328 samples with both genotype and expression data 
from tumorous breast tissue remained in the analysis. The 
normalization of mRNA expression data (Illumina HT-12 
v3 platform) was performed by quantile normalization 
utilizing single target distribution, described in detail 
elsewhere [44]. The cis- eQTL analysis was conducted 
with R-package Matrix eQTL [46] using linear regression 
and ANOVA models. 
Functional annotation of variants
Linkage disequilibrium and the haplotype blocks in 
the SNP regions were examined based on r2 using SNAP 
[47]. To annotate the sequences surrounding our SNPs of 
interest for regulatory elements we searched ENCODE 
(Encyclopedia Of DNA Elements) data using Haploreg 
v2 [48] and RegulomeDB [49]. ENCODE project has 
conducted high throughput functional assays such as 
Formaldehyde-Assisted Isolation of Regulatory Elements 
(FAIRE), Chromatin immunoprecipitation (ChIP), and 
DNaseI hypersensitivity (HS) to evaluate non-coding 
functional sequences and regulatory elements such as 
promoters, enhancers and silencers [50].
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